Brain Aging and Dysregulated Protein Phosphorylation in Alzheimer Disease
Altered phosphorylation patterns of some proteins may have implications for sporadic Alzheimer disease.
Alzheimer Disease and Dementia
Tau Positron Emission Tomography Better Predicts Cognitive Decline Among Patients With Alzheimer Disease
The researchers sought to understand the prognostic value of tau positron emission tomography for predicting cognitive decline across the clinical spectrum of Alzheimer disease.
Relapse Risk for Psychosis in Dementia Lower With Continued Pimavanserin
For patients with dementia-related psychosis who have a response to pimavanserin, the risk for relapse is lower with continuation of the drug versus discontinuation
Global Prevalence of Young-Onset Dementia Examined
The overall global age-standardized prevalence of young-onset dementia, in which symptoms start before age 65 years, is 119.0 per 100,000 population.
Two Major Health Systems Will Not Administer Controversial Aduhelm
Individual doctors can prescribe Aduhelm, but patients would have to go elsewhere to receive the drug via infusion
First Alzheimer Disease Prevention Trial Using Amyloid-Targeting Drugs Gantenerumab or Solanezumab
The researchers conducted a randomized, placebo-controlled, multi-arm trial of gantenerumab or solanezumab in participants with dominantly inherited Alzheimer disease across asymptomatic and symptomatic disease stages.
Longer Reproductive Window Could Increase Risk for Alzheimer Disease
A longer reproductive period in women is associated with biomarkers for Alzheimer disease (AD).
Aduhelm Label Update Clarifies Patient Population Studied in Trials
The treatment, which is administered as a monthly intravenous infusion, binds to aggregated β-amyloid and promotes removal of amyloid from the brain.
Blood-Based Biomarkers May Predict Alzheimer’s Disease Risk
Determining if a patient with subtle cognitive symptoms suffers from prodromal or preclinical Alzheimer disease (AD) and whether that patient will progress to AD dementia is a challenge. However, this determination is critically important in order to ascertain a correct and early diagnosis of AD. Researchers may have found one method that can help.
House Committees to Investigate New Alzheimer Disease Drug Approval
The U.S. FDA’s controversial approval of a new drug for AD, along with its high price, is now being investigated by two House committees.
- Loading...
Loading...
Next post in Alzheimer's Disease and Dementia
Loading... 
Loading...